Literature DB >> 19028033

The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy.

A Gompel1, S Rozenberg, D H Barlow.   

Abstract

Hormone therapy is still the most commonly used treatment to relieve menopausal symptoms and the consequences of oestrogen deficiency. The decision process is complex and benefits needs to be balanced vs. risks. Not all reported benefits and risks have been as well highlighted by the media throughout recent years, it is therefore important to update regularly the current scientific knowledge. This is an actualization of the last EMAS statement concerning hormone replacement therapy use.

Mesh:

Year:  2008        PMID: 19028033     DOI: 10.1016/j.maturitas.2008.10.009

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  10 in total

Review 1.  Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.

Authors:  Wendy Y Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-12       Impact factor: 4.741

Review 2.  Influence of lifestyle factors on breast cancer risk.

Authors:  Max Dieterich; Johannes Stubert; Toralf Reimer; Nicole Erickson; Anika Berling
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

3.  Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Authors:  Rowan T Chlebowski; JoAnn E Manson; Garnet L Anderson; Jane A Cauley; Aaron K Aragaki; Marcia L Stefanick; Dorothy S Lane; Karen C Johnson; Jean Wactawski-Wende; Chu Chen; Lihong Qi; Shagufta Yasmeen; Polly A Newcomb; Ross L Prentice
Journal:  J Natl Cancer Inst       Date:  2013-03-29       Impact factor: 13.506

Review 4.  Postmenopausal hormone therapy: risks and benefits.

Authors:  Serge Rozenberg; Jean Vandromme; Caroline Antoine
Journal:  Nat Rev Endocrinol       Date:  2013-02-19       Impact factor: 43.330

Review 5.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

6.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

7.  Guidelines and recommendations on hormone therapy in the menopause.

Authors:  Amos Pines
Journal:  J Midlife Health       Date:  2010-01

8.  Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study.

Authors:  Joanne Ryan; Marianne Canonico; Laure Carcaillon; Isabelle Carrière; Jacqueline Scali; Jean-Francois Dartigues; Carole Dufouil; Karen Ritchie; Pierre-Yves Scarabin; Marie-Laure Ancelin
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

9.  Menopausal Hormone Therapy, can we safely use it in women with co-morbidities?

Authors:  Duru Shah
Journal:  J Midlife Health       Date:  2015 Jan-Mar

Review 10.  Roles of Hormone Replacement Therapy and Menopause on Osteoarthritis and Cardiovascular Disease Outcomes: A Narrative Review.

Authors:  Yixue Mei; Jennifer S Williams; Erin K Webb; Alison K Shea; Maureen J MacDonald; Baraa K Al-Khazraji
Journal:  Front Rehabil Sci       Date:  2022-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.